Kodiak Sciences (KOD) Preferred Stock Liabilities (2017 - 2018)
Kodiak Sciences' (KOD) quarterly Preferred Stock Liabilities came in at $50.0 million in Q3 2018, little changed on a QoQ basis from $50.0 million in Q4 2017.
Powered by 
Analysis
Kodiak Sciences (KOD) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Kodiak Sciences (KOD) has 2 years of Preferred Stock Liabilities data on file, last reported at $50.0 million in Q3 2018.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $50.0 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $50.0 million (changed N/A YoY) and the FY2017 annual result came in at $50.0 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $50.0 million in Q3 2018, from $50.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $50.0 million in Q4 2017 to a low of $50.0 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | - |